Publications by authors named "Seiya Tada"
Article Synopsis
- Ramucirumab is a targeted therapy for advanced hepatocellular carcinoma (HCC) in patients with high levels of alpha-fetoprotein (AFP) after failing initial treatments, particularly Sorafenib.
- A study of 33 patients revealed that improving albumin-bilirubin (ALBI) scores during treatment correlated with better outcomes and prognosis.
- Patients who continued treatment after ramucirumab failure and had good ALBI scores at the beginning saw significantly better prognoses compared to those who did not pursue further therapy.
To evaluate the efficacy of atezolizumab plus bevacizumab treatment in patients with hepatocellular carcinoma (HCC) previously treated with molecular targeted agents (MTAs). Thirty-one patients treated with atezolizumab plus bevacizumab for unresectable HCC and previously treated with MTAs were enrolled in this study. The treatment lines ranged from second to sixth lines.
View Article and Find Full Text PDFHemophagocytic lymphohistiocytosis (HLH) is a life-threatening syndrome that occurs as a complication in many clinical settings. Malignancy-associated HLH develops in patients with hematopoietic neoplasms, particularly in those with lymphoma, and its development in those with myelodysplastic syndrome (MDS) is uncommon. We herein report a case of HLH in a patient with low-risk MDS that was successfully treated with azacitidine.
View Article and Find Full Text PDF